ALT (alanine aminotransferase)

Reference ranges

Optimal ranges are tighter than standard lab ranges and reflect functional-medicine targets, not the populations they were derived from. Reference bands depend on sex, age, and circumstance — Juno's lab analysis layers your profile context onto the printed range when you paste a value.

Peptide relevance

BPC-157 has shown hepatoprotective effects in animal models — could lower ALT or prevent rises. Tirzepatide / Semaglutide reduce ALT in NAFLD/MASH patients (subset of SURMOUNT-MASH trial). CJC-1295 + Ipamorelin: no consistent ALT effect documented. KEY CONFOUNDERS: intense eccentric training in last 48-72h raises ALT 2-5x transiently (muscle origin, not liver); alcohol; statins (rare); high-dose acetaminophen. Anabolic-androgenic steroids (NOT peptides but often co-used) can elevate ALT substantially.

Peptides that influence this marker

Documented to affect this marker. Click through for the full evidence-tiered profile.

• 5-Amino-1MQ
  NNMT inhibitor (small molecule)

  NNMT inhibitor active in liver — preclinical hepatoprotective signals

• Glutathione
  Tripeptide antioxidant (companion supplement)

  Hepatoprotective antioxidant — supports phase II liver detoxification

• MK-677 (Ibutamoren)
  Non-peptide ghrelin mimetic (small molecule)

  Oral peptide — hepatic processing; monitor liver enzymes during sustained use

• NAD+
  Coenzyme

  Cellular cofactor — supports hepatic NAD pool and mitochondrial function

• Tier 1 — Human RCTRetatrutide↓· 12–24 weeks
  GLP-1 / GIP / glucagon triple agonist
• Tier 1 — Human RCTTesamorelin↓· 12–26 weeks
  GHRH analog

  Only relevant when used in a fatty-liver context with elevated baseline enzymes.

• Thymosin Alpha-1
  Immunomodulatory peptide

  Immune modulator — used clinically as adjunct in hepatitis B/C protocols

• Tier 1 — Human RCTTirzepatide↓· 12 weeks
  GLP-1 / GIP dual agonist

  Relevant in a fatty-liver context with elevated baseline enzymes.